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Cytotoxic T lymphocytes (CTL) recognize viral and cellular antigens in associa-
tion with class I glycoproteins encoded in the host MHC (1). The recognition event
results from a cell surface interaction between the CTL and the target cell, but it
has been conclusively demonstrated in a wide variety of systems that many virus
proteins that are not detectable by standard methods on the cell membrane are,
nevertheless, detected by CTL (2, 3). These observations have spawned many ex-
perimentstocharacterizethe precisenature oftheMHC/antigencomplexwithwhich
CTL interact. It has been demonstrated that short peptides, some comprising only
seven amino acids, can, when applied exogenously to uninfected target cells, sensi-
tize them toCTL recognition and lysis; such sensitization, however, usually has re-
quired a vast molar excess ofpeptide to target cells (often used at 10-5 M, which
may represent ti1011 peptide molecules per target cell) (4-6). Since it is likely that
class I MHC generally presents antigens that are synthesized within the presenting
cell, andnot antigens applied in grossexcess tothe cell surface (7), wehaveattempted
to ascertain the ability ofclass I MHC to detect and present a known CTL epitope
when it is synthesized within a cell in the form ofan extremely short polypeptide
molecule thatwe have chosen to term an "endogenous peptide."We show that a nine
amino acid epitope, when flanked by a minimal number ofneighboring residues,
is sufficient to allow virus-specific MHC-restricted recognition by bulk and cloned
CTL.
We have used as a model system the infection by lymphocytic choriomeningitis
virus (LCMV) of its natural murine host. Acute LCMV infection induces a brisk
primary CTL response, readily detectable by in vitro assay(8); the response is bio-
logically relevant, being instrumental in effecting viral clearance from the host (9).
Early attempts to assign CTL recognition relied uponthe use ofsegmental reassor-
tantsofthis bisegmented RNA virus, and identified theviral Ssegment asencoding
the target molecules (10). This segment encodes two proteins, a 558 amino acid
nucleoprotein and a 498 glycoprotein (11, 12) that undergoes posttranslational
modification to yield the two virion glycoproteins GP-1 and GP-2 (residues 1-262
and 263-498, respectively) (13). We have expressed these proteins in vaccinia virus
(14), and have generated families of recombinant viruses expressing serially trun-
cated LCMV genes (5). These recombinants have been used to map CTL epitopes
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on several different MHC backgrounds, and we have shown that epitopes differ in
a manner dictated by the class I molecules themselves (14). On the H2b haplotype
(in C57BL/6 mice) we identified three discrete epitopes, two on the viral glycopro-
tein and one on the nucleoprotein. One of the glycoprotein epitopes was further
characterized using nested sets of synthetic peptides, which allowed the delineation
of a nine amino acid core sequence comprising the minimal CTL epitope (6). The
sequence, VENPGGYCL, lies near the NH2 terminus of GP-2, at residues 278-286.
Its sequence suggests that it is neither amphipathic nor an a-helix, and it lacks a
motifproposed as predictive for T cell epitopes; thus, simple sequence analysis would
have failed to highlight this region as a potential epitope. The nonameric peptide,
when applied exogenously to H2b target cells, sensitizes it to lysis both by cloned
CTL and primary CTL from an acutely infected mouse (6). This lysis is maximal
at peptide concentrations of51AM, and half-maximal at 0.1 /AM. This latter concen-
tration represents N10'3 molecules in each 200-p1 in vitro assay, each of which con-
tains 2 x 104 target cells. Thus, 5 x 108 peptide molecules per target cell are re-
quired to achieve half-maximal lysis. These peptide concentrations are similar to
those used by other groups to sensitize target cells (4).
The ability of extremely short peptides to sensitize targets to CTL lysis in vitro
is often cited as evidence that in vivo presentation of virus antigen by class I MHC
occurs by an identical mechanism. We would argue that the fact that CTL can see
targets sensitized using a great molar excess of peptide does not constitute evidence
that peptide is the form normally encountered, and certainly does not demonstrate
the ability of target cells to process/present such molecules under normal circum-
stances. Since it is hypothesized that MHC may function in vivo by "screening" short
peptides that result from degradation of endogenously synthesized proteins, it is critical
to determine whether MHC can in fact detect such short molecules. The purpose
ofour experiment is, therefore, to establish whether very short sequences made within
a virus-infected target cell can be presented to CTL.
Materials and Methods
Cell Lines, Viruses, andMouseStrains.
￿
BALB C17 (H2dd) and MC57 (1-12b) cells were grown
as described (14). LCMV (Armstrong strain) and recombinant vaccinia viruses were made
by standard techniques, as described (5). All recombinant plasmids were subjected to DNA
sequencing to ensure that theirstructure was as intended. The mouse strains used were BALB/c
(H2dd) and C57BL/6 (H266).
Analysis ofLCMV-sped RNAs Produced by Recombinant Vaccinia.
￿
143 TK- (human osteosar-
coma) cells were infected with recombinant vaccinia at a multiplicity of infection (moi) of
3, and 4 h after infection total cytoplasmic RNA was prepared as previously described (5),
subjected to Northern blot transfer, and probed with a '2P-labeled fragment of the LCMV
GP cDNA. After washing (final stringency 0.2 x SSC, 0.5% SDS, 55°C) the filter was ex-
posed to photographic film.
Preparation ofEffector CellsforIn Vitro Cytotoxicity Assay.
￿
Effector cells for this assay were:
(a) Primary anti-LCMV splenocytes prepared by inoculation of 2 x 105 PFU of LCMV in-
traperitoneally; 7 d later (9 d for mice infected with the LCMV PAST strain) the mouse
was killed, and splenocytes were harvested. (b) Primary anti-vaccinia CTL spleens were har-
vested 6 d after inoculation of 2 x 106 PFU i.p. of VVSC . (c) Many assays involved the
use of CTL clones. The isolation and maintenance of these cells is as described (5).
In VitroCytotoxicityAssay.
￿
This procedure has been described elsewhere (5). Peptides, where
used, were weighed and suspended in medium immediately before addition to the assay, and
remained in the well at the stated concentration throughout the assay.WHITTON AND OLDSTONE
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Results
Construction of Recombinant Viruses Expressing an LCMV Minigene.
￿
Using serially
deleted LCMV GP molecules we have shown that the VENPGGYCL epitope can
be recognized in avaccinia construct in which several non-LCMV residues are cova-
lently attached to the COOH terminus ofa truncated GP encoding residues 1-293
(5) . We havenowmadearecombinant virus encoding only 22 amino acids (272-293)
of the LCMV GP-2 molecule, followed by termination codons in all three reading
frames andlacking thenon-LCMVCOOH-terminal residues (Fig. 1 A) . This recom-
binant virus, named VVg, directsthetranscription ofa singleLCMVspecific RNA
species of the appropriate size, as detected by Northern blot analysis (Fig . 1 B) . We
have analyzed five independent isolates oftherecombinant, and allbehave identically.
CTL Efficiently Recognize theMinigene Protein Product.
￿
Fig. 2 shows that target cells
infected with VVg are lysed both by aCTL clone (HL 2-2-8) specific for this epi-
tope, and by bulk CTL. Lysis is epitope specific, since HL 2-2-8 fails to lyse cells
infected with VVf(a recombinant expressing adifferentLCMV epitope contained
in GP residues 1-173 and which is recognized by bulk CTL), and is H2 restricted .
FIGURE 1 .
￿
(A)TheLCMVCTLepitope sequences expressedfrom recombinant vaccinia virus
VVg . TheS RNAsegment ofLCMV, which encodesGP andNP, is shown, alongwith theamino
acid sequence of the CTL epitope under analysis . TheDNA sequence encoding these residues
was directly apposed to a translation termination cartridge containing stop codons in all three
reading frames, to prevent the synthesis of a 3' fusion protein, and thereafter cloned into apUC
derivative to place the plasmid ATG in frame with the LCMV sequences. This minigene was
cloned into the vaccinia transfer plasmid pSCll, and at this stage (immediately before introduc-
tion into vaccinia virus)the minigeneDNAsequence was confirmed by the chemical degradation
technique. (B) ANorthern blot analysis ofRNA produced byVVg. Total cytoplasmicRNAwas
prepared as previously described (5)from cells infected with either offour recombinant vaccinia .
VVfand VVhcontain fragments of LCMV GP encoding residues 1-173 and 241-293, respec-
tively. VVg is described in A. VVSC11 is a control recombinant that contains no LCMV se-
quences . The blot was hybridized with a strand-specific probe from the LCMV GP, washed,
and exposed to photographic film . The sizes of marker RNA molecules are shown (kb).1036
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Thus the LCMV amino acid sequences encoded in VVg are expressed in recogniz-
able form. That they are being expressed in the form ofthe short peptide encoded
by the sequence-confirmed open reading frame, rather than as part of a longer fu-
sion protein, is suggested by a series offacts. First, the mRNA is ofthe correct size,
indicating that the cap and termination sites are as anticipated. Second, there is
only one ATG signal between the cap site and the epitope sequence, indicating that
an erroneous start(and hence a potential 5' fusion) isvery unlikely. Third, inadver-
tent production ofa 3' fusion protein could occur ifthere were a specific rearrange-
mentbeginning precisely at the last base ofthe ORF epitope sequence anddeleting
the translation termination codons that lie in all frames immediately downstream.
This unlikely possibility is rendered vanishingly improbable because all five inde-
pendent isolates of the recombinant (isolated in separate experiments) are recog-
nized by CTL. We therefore conclude that the short ORF most probably is trans-
lated to produce an endogenous peptide, which can be presented by class I MHC.
VVg contains the immunodominant LCMV epitope VENPGGYCL recognized
by H-2b-restricted CTL (6). Note that recognition by CTL clones ofVVg-infected
cells is approximately equivalent to that of LCMVinfected cells (Figs. 2 and 3).
Hence the foreshortenedmolecule is processed/presented as satisfactorily as the na-
tive, by the criterion of CTL lysis.
TheMinigene Product Is Presented by the "Endogenous"Route.
￿
The formal possibility
remained that target cells were sensitized not by MHC presentation ofthe endoge-
nous peptide, but rather by secretion ofthe short molecule, with subsequent ex-
ternal attachment to MHC. We therefore incubated unlabeled VVg-infected H2b
cells along with "Cr-labeled uninfected H2b cells. CTL lysis oflabeled, uninfected,
cells did not occur(Fig. 3, column 4), indicatingthatthe labeledcells were not coated
with peptidesecreted from neighboringVVg-infected cells. Itis, therefore, very likely
that recognition/lysis ofVVg infected cells (Fig. 2, and Fig. 3, column 3) results
from CTL recognition ofvirus antigen presentedby the"endogenous" pathway usu-
ally used by class I glycoproteins.
Discussion
Togethertheseresultsshow that aCTLepitope madeas ashortpeptide andlacking
extensive neighboring residues can be properly processed and presented by class
I MHC. This atteststo the sensitivity and flexibility ofthe MHC screening system,
and representsthe first direct evidence thatclass I MHC molecules arein factcapable
(C57BL/6) bulk splenocytes, or with H2-mismatched (BALB/c) bulk splenocytes. Aftera 5-h incuba-
tion, supernatants were harvestedandtheirradioactivity wascounted. Levels ofCr releasesignificantly
above background are boxed.
E:T UN LCMV
H-2 b
vvg vv t vvsC11
FIGURE 2. VVgis recognized by bulk CTL and
by CTLclones. An in vitrocytotoxicity assaywas
carriedoutas previously described(5). In brief,
H2b aLCMV so 3 65 16 3 H2b (MC57) target cells were infected with ei-
Splenocytes 25 1 s2 s 4 ther LCMV, VVg, VVf(containing LCMV GP
2 0 1-173, whichharborsasecond CTLepitope), or
HL 2-2-8
aGP278-286
5
2.5
7
3
46
44 0 o VVSCII (which contains no LCMV sequences).
H2dcLCMV so 0 4 1 2 1 UN, uninfected cells. The "Cr-labeled target
Splenocytes 25 1 1 1 2 1 cells were incubated with an H2-matched CTL
clone (HL 2-2-8) that is specific for the GP
272-283 epitope (7) or with H2-matchedWHITTON AND OLDSTONE
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FIGURE 3.
￿
VVg sensitizes cells by
the endogenous (natural) route. An
. .
. . ut, as described in thelegend
mixture
to Fig 2. In this case, however, target
cells were used (VVg infected +
uninfected) that comprised a 1 :1
. "Cr-labeled
unlabeled
uninfected
co-incubated for I h before the 5-h
assay. CTL clones 2-2-8 and 2-3-2
are specific for GP 272-293 e i p
topes and are restricted by Db (6).
of such a feat. We (5) and others (15) have previously shown that incomplete genes
can generate recognizable CTL epitopes, but in all of these constructs the epitope
was translated in a protein significantly larger than the "minigene" reported here.
Our results further suggest that unresolved density found in the antigen binding
groove oftherecently crystallized HLA-A2 molecule (16)may indeed reflectthe pres-
ence of the actual peptide bound and presented by MHC, rather than merely the
result of proteolysis of a larger molecule (which could have occurred during the
purification of HLA-A2, a procedure that itself involved proteolysic digestion).
Wherethe classIMHC molecule, aglycoproteinsynthesizedonmembrane-bound
ribosomes of the rough endoplasmic reticulum, meets with and binds the endoge-
nouspeptide, which lacks anysignal sequence and presumably is translatedbycyto-
plasmic ribosomes, remainsan open question, but onethat isbeingexplored withvigor.
Our results, therefore, further delimit the minimal sequences needed for target
cell recognition by CTL. However, evidence to clarify the virus sequence require-
ments for induction ofCTL presently remains elusive, in part because it has proven
difficult to induce class I-restricted CTL using soluble protein or peptide; hence
these reagents are of limited value in assessing induction requirements. CTL are
best inducedby a replicatingagent, and materials such as VVg, which express very
limited viral sequences but remain recognizable by CTL, will be invaluable in as-
sessing the viral sequence requirements for the induction of CTL responses.
Summary
Since class I MHC glycoproteins may function by"screening and selecting"degraded
proteins, we wished to determine whether very short peptides made within a cell
were detected and bound by MHC, and presented for T cell perusal. We show that
a 22 amino acid viral sequence containing a Db-restricted nonameric CTL epitope
is sufficient to direct CTL recognition/lysis ofH2b target cells. The mechanism of
epitope presentation is by the"natural" endogenous route, and appearsto direct lysis
as effectively as wild-type virus infection, in which the epitope is part of a 236 res-
idue glycoprotein.
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